From: Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis
Total number of invasive candidiasis episodes | 28 |
Distribution of invasive Candida species | - |
C. albicans | 4 |
C. glabrata | 8 |
C. krusei | 4 |
C. norvegensis | 3 |
C. inconspicua | 2 |
C. dubliensis | 2 |
C. parapsilosis | 2 |
C. kefyr, C. guilliermondii, C. tropicalis (each 1) | 3 |
Gender | Â |
Number of males | 12 (42.9%) |
Number of females | 16 (57.1%) |
Median age in years | 47 (31–63 IQR) |
Underlying conditions: | Â |
Number of patients with: | Â |
Acute myeloid leukaemia | 16 |
Acute lymphatic leukaemia | 3 |
Myelodysplastic syndrome | 3 |
Non-Hodgkin lymphoma and plasmocytoma (2 each) | 4 |
Aplasia of unknown origin, hereditary mitochondropathy (1 each) | 2 |
Haematological treatments | Â |
Number of allogeneic HSCT recipients | 15 |
PBSC recipients | 13 |
BMT recipient | 1 |
Cord blood recipient | 1 |
Related/unrelated donor | 1/14 (6.7%/93.3%) |
Conditioning chemotherapy before HSCT | 2 |
Induction chemotherapy | 8 |
Other chemotherapies (e.g. consolidation, not specified) | 3 |
Other risk factors for invasive candidiasis | Â |
A stay in the ICU within 7 days prior to onset of invasive candidiasis | 4 |
Number of patients in neutropenia (<500/uL) at time of invasive candidiasis | 19 |
Median duration (days) of neutropenia until diagnosis of invasive candidiasis | 13 (7–24 IQR) |
Number of patients with CMV disease before invasive candidiasis episode | 2 |
Number of patients with onset of GvHD before invasive candidiasis | 5 |
Outcome | Â |
Death (all cause) within 30 days after diagnosis of invasive candidiasis | 10 |